Evidence map›Paper›PMID 27576583›Full record

ArticleJournal of neuroinflammation2016

Modulatory effects of perforin gene dosage on pathogen-associated blood-brain barrier (BBB) disruption.

Robin C Willenbring, Fang Jin, David J Hinton, Mike Hansen, Doo-Sup Choi, Kevin D Pavelko, Aaron J Johnson

Open access · goldAbstract read
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Conditional Silencing of H-2DJournal of immunology (Baltimore, Md. : 1950) · 2020
    Article
  14. Article
  15. Review
  16. Human perforin gene variation is geographically distributed.Molecular genetics & genomic medicine · 2018
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Robin C WillenbringMayo Graduate School, Mayo Clinic, Rochester, MN, USA.
Fang JinDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
David J HintonMayo Graduate School, Mayo Clinic, Rochester, MN, USA.
Mike HansenDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
Doo-Sup ChoiDepartment of Neurology, Mayo Clinic, Rochester, MN, USA.
Kevin D PavelkoDepartment of Immunology, Mayo Clinic, Rochester, MN, USA.
Aaron J JohnsonDepartment of Immunology, Mayo Clinic, Rochester, MN, USA. Johnson.aaron2@mayo.edu.
Mayo Clinic in Arizona · USMayo Clinic · USWinnMed · US

Funding

CD 8 T Cell Mediated Disruption of Blood Brain Tight JunctionR01NS060881 · NINDS · UNIVERSITY OF CINCINNATI · PI JOHNSON, AARON J · 2009 to 2013
$1.7M
CD8 T cell mediated disruption of Blood Brain Barrier Tight JunctionsR56NS094150 · NINDS · MAYO CLINIC ROCHESTER · PI JOHNSON, AARON J · 2016 to 2016
$398k
NINDS NIH HHS R01 NS060881NINDS NIH HHS R56 NS094150
6 · The paper itself

Abstract

backgroundCD8 T cell-mediated blood-brain barrier (BBB) disruption is dependent on the effector molecule perforin. Human perforin has extensive single nucleotide variants (SNVs), the significance of which is not fully understood. These SNVs can result in reduced, but not ablated, perforin activity or expression. However, complete loss of perforin expression or activity results in the lethal disease familial hemophagocytic lymphohistiocytosis type 2 (FHL 2). In this study, we address the hypothesis that a single perforin allele can alter the severity of BBB disruption in vivo using a well-established model of CNS vascular permeability in C57Bl/6 mice. The results of this study provide insight into the significance of perforin SNVs in the human population.

methodsWe isolated the effect a single perforin allele has on CNS vascular permeability through the use of perforin-heterozygous (perforin+/-) C57BL/6 mice in the peptide-induced fatal syndrome (PIFS) model of immune-mediated BBB disruption. Seven days following Theiler's murine encephalomyelitis virus (TMEV) CNS infection, neuroinflammation and TMEV viral control were assessed through flow cytometric analysis and quantitative real-time PCR of the viral genome, respectively. Following immune-mediated BBB disruption, gadolinium-enhanced T1-weighted MRI, with 3D volumetric analysis, and confocal microscopy were used to define CNS vascular permeability. Finally, the open field behavior test was used to assess locomotor activity of mice following immune-mediated BBB disruption.

resultsPerforin-null mice had negligible CNS vascular permeability. Perforin-WT mice have extensive CNS vascular permeability. Interestingly, perforin-heterozygous mice had an intermediate level of CNS vascular permeability as measured by both gadolinium-enhanced T1-weighted MRI and fibrinogen leakage in the brain parenchyma. Differences in BBB disruption were not a result of increased CNS immune infiltrate. Additionally, TMEV was controlled in a perforin dose-dependent manner. Furthermore, a single perforin allele is sufficient to induce locomotor deficit during immune-mediated BBB disruption.

conclusionsPerforin modulates BBB disruption in a dose-dependent manner. This study demonstrates a potentially advantageous role for decreased perforin expression in reducing BBB disruption. This study also provides insight into the effect SNVs in a single perforin allele could have on functional deficit in neurological disease.

Indexed as

AnimalsBlood-Brain BarrierBrainGene DosageMagnetic Resonance ImagingMiceMice, Inbred C57BLMice, KnockoutMice, TransgenicPore Forming Cytotoxic ProteinsTheilovirusperforin, mousePore Forming Cytotoxic ProteinsBBB disruptionCD8 T cellsPerforinPerforin single nucleotide variantsPIFSTMEV

Identifiers

PMID27576583
PMCPMC5006384
OpenAlexW2513517505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.